Adjuvanted vaccines for avian infectious bronchitis using t-vant
T-vant is a novel adjuvant compatible with various immunogens to induce immune responses and protective efficacy equivalent to live vaccines. It offers safety, stability, and cost-effectiveness, and is at TRL 8 with proven efficacy in various animal models.
Overview
T-vant is an innovative adjuvant developed to enhance vaccine efficacy, offering a promising alternative to traditional live attenuated vaccines. Its versatility allows it to be combined with a wide range of immunogens, including peptides, proteins, and viral particles, to elicit both systemic and mucosal immune responses. T-vant has demonstrated its effectiveness in inducing immunity and protective efficacy equivalent to or better than existing market adjuvants across several diseases, such as pertussis, SARS-CoV-2, and Ebola. This makes it an ideal candidate for developing vaccines against avian infectious bronchitis, aiming to improve safety and reduce manufacturing time.
Technical specifications
- Compatibility: Can be admixed with various immunogens, including inactivated viruses
- Performance: Proven to elicit immune responses equivalent to live vaccines
- Applications: Effective in rodent and non-human primate models for diseases like Salmonella and Lyme disease
- Manufacturing: Highly stable and inexpensive to produce
- Validation: Supported by extensive immunogenicity and efficacy data from NIH and DTRA programs
Technology readiness level
T-vant is at Technology Readiness Level 8, indicating that it has been thoroughly tested and validated in relevant environments, with extensive data supporting its safety and efficacy. The adjuvant is ready for integration into vaccine manufacturing processes and further collaborative development.
About Tulane University
Tulane University is a private research institution in New Orleans with comprehensive academic breadth and a collaborative, cross-disciplinary culture. Co-located university and medical campuses anchor the city’s healthcare corridor, enabling access to clinicians, patients, and clinical trial infrastructure. Proximity to hospitals, downtown laboratories, and shared core facilities enables rapid collaboration with startups and established firms, while a major primate research center and Gulf Coast field sites expand options for preclinical studies. Research is supported by competitive federal funding from agencies such as NIH, NSF, and DOE, alongside industry-sponsored agreements. A dedicated technology transfer office manages IP, licensing, and startup formation with streamlined contracting and corporate engagement.
delivered to your inbox.